Thai Health Minister Visits China To Expand Vaccine Cooperation With Innovax
Thai Minister of Public Health Prawatth Phromphat visited Xiamen Innovax Biotech Co Ltd headquarters and production base in Xiamen, Fujian Province, China, on November 18. The visit aimed to discuss expanding vaccine cooperation beyond the existing HPV 9-valent vaccine technology transfer. This high-level engagement seeks to develop new innovative vaccines specifically for shingles and respiratory syncytial virus or RSV. The Thai government proposed elevating Thailand to become a regional manufacturing and export hub for vaccines across the Association of Southeast Asian Nations or ASEAN.
Expanding Vaccine Partnerships
The existing HPV 9-valent vaccine, Preventra9, was registered by the Thai Food and Drug Administration or FDA in July 2026. Preventra9 represents the first vaccine of its kind approved outside the People's Republic of China. This vaccine was developed through a technology transfer partnership between Innovax and Global Biotech Products Co Ltd of Thailand. Academic support for this development came from the National Vaccine Institute or NVI.
Innovax is a biotechnology company operating under the Wantai BioPharm group. Innovax holds patents for an E. coli-derived Virus-Like Particle or VLP technology platform. This VLP platform allows for large-scale production that meets World Health Organization Prequalification and PIC/S GMP standards. Prawatth Phromphat stated that Innovax is a leading biotechnology company under the Wantai BioPharm group, holding patents for an E.
Innovax Production Capabilities
Innovax has previously produced several vaccines using its established technology. The company has manufactured Hepatitis E vaccine known as Hecolin. Additionally, Innovax has produced HPV 2-valent vaccine named Cecolin and HPV 9-valent vaccine named Cecolin 9. These past productions demonstrate the company's capacity for vaccine manufacturing under stringent international quality standards.
The collaboration discussed during the visit focuses on leveraging Innovax's VLP technology for future vaccine development. The VLP platform is designed to facilitate large-scale manufacturing processes efficiently. This technological foundation supports the Thai government's ambition to establish regional vaccine production capabilities within ASEAN. The Minister's visit underscores a strategic focus on bolstering regional public health infrastructure through international partnerships.
Regional Manufacturing Ambitions
The Thai government's proposal to elevate Thailand to a regional manufacturing and export hub for vaccines in ASEAN represents a significant economic and public health objective. This initiative aims to secure regional health supply chains against future disruptions. By establishing such a hub, Thailand seeks to become a central player in regional biopharmaceutical production. The partnership with Innovax provides a direct pathway to realizing this strategic manufacturing goal.
The ongoing discussions between the Thai Ministry of Public Health and Innovax represent a critical step in advancing vaccine accessibility across Southeast Asia. The expansion of cooperation beyond the existing HPV 9-valent vaccine technology transfer will focus on developing shingles and RSV vaccines. These new vaccine candidates address significant unmet public health needs across the region. The successful implementation of these partnerships will solidify Thailand's role in regional healthcare security.
Glossary
- RSV — RSV is a respiratory syncytial virus. The expansion of cooperation will focus on developing shingles and RSV vaccines.
- Association of Southeast Asian Nations — The Association of Southeast Asian Nations is a political, economic, security, military, educational and socio-cultural organization of countries located in Southeast Asia. Its aim is to foster cooperation and mutual assistance among members.
- ASEAN — ASEAN is an intergovernmental forum of all 11 states in Southeast Asia. ASEAN primarily focuses on Southeast Asian economic development, peaceful coexistence and adherence to international norms.
- HPV 9-valent vaccine — Gardasil 9 (HPV 9-valent vaccine, Recombinant) is a brand-name vaccine. It is used to help prevent HPV and certain HPV complications, including cervical cancer.
- respiratory syncytial virus — Respiratory syncytial virus (RSV), also called human respiratory syncytial virus (hRSV) and human orthopneumovirus, is a virus. It causes infections of the respiratory tract.
This article was written with AI assistance from multiple news reports and is reviewed by our editors under our editorial principles. Editorial Standards · Tips & Contact
Comments 0